½ÃÀ庸°í¼­
»óǰÄÚµå
1541658

¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀå º¸°í¼­ : Á¦Ç° À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Blood Purification Equipment Market Report by Product Type (Portable, Stationary), Indication (Sepsis, Renal Diseases, and Others), End User (Hospitals and Clinics, Dialysis Centers, and Others), and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 137 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀå ±Ô¸ð´Â 2023³â 209¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ¾ÕÀ¸·Î IMARC GroupÀº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 6%¸¦ ³ªÅ¸³¾ Àü¸ÁÀ̸ç 2032³â±îÁö 359¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

Ç÷¾× Á¤È­ Àåºñ¶õ ȯÀÚÀÇ Ç÷¾×À» ÃßÃâ,Á¤È­Çϱâ À§ÇÑ ÀÇ·á±â±â¸¦ ¸»ÇÕ´Ï´Ù. ºÒ¼ø¹°À» Á¦°ÅÇϱâ À§ÇØ Ç÷¾×À» Á¦°ÅÇϰí Á¤È­µÈ Ç÷¾×À» ÆßÇÁ·Î ü³»·Î µÇµ¹¸³´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â Àåºñ·Î´Â Ç÷¾× Åõ¼®, Ç÷¾× ¿©°ú, Áö¼ÓÀûÀÎ ½ÅÀå ´ëü ¿ä¹ý(CRRT), Ç÷¾× °ü·ù, Ç÷Àå ±³È¯ ÀåÄ¡ µîÀÌ ÀÖ½À´Ï´Ù. À̵éÀº ÀϹÝÀûÀ¸·Î Àå±â ºÎÀüÀ̳ª ½ÅºÎÀü, ¸é¿ª ´ë»ç ÀÌ»óÀÇ Ä¡·á³ª ÇöóÁ Æä·¹½Ã½º Ä¡·á¿¡ ÀÌ¿ëµÇ¾î º´¿ø, Ŭ¸®´Ð, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µî¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

Ç÷¾× Á¤È­ Àåºñ ½ÃÀå °æÇâ

¼¼°èÀÇ ´ë»ç, ¸é¿ª, ½ÅÀå °ü·Ã ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´, °íÇ÷¾Ð, ½ÅºÎÀü µîÀÇ Áúº´¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡°¡ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Äڷγª¹ÙÀÌ·¯½ºº´(COVID-19)ÀÌ °è¼Ó È®»êµÇ°í ÀÖ´Â °¡¿îµ¥, ÀÇ·á¼¾ÅÍ Àüü¿¡¼­ Ç÷¾×Á¤È­ÀåÄ¡¿¡ ´ëÇÑ ¿ä±¸°¡ ´ëÆø Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÄ¡´Â Ç÷¾×¿¡¼­ º´¿øÃ¼, »çÀÌÅäÄ«ÀÎ ¹× ±âŸ ¿°Áõ¼º ¸Å°³Ã¼¸¦ ¿©°úÇÏ¿© ¼¼Æ÷ÀÇ ¸é¿ª ¹ÝÀÀÀ» °³¼±ÇÕ´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿ÀÇǵå¹é ·çÇÁ¿Í °³º°È­µÈ Åõ¼®Ã³¹æ ±â´ÉÀ» °®Ãá ÀåÄ¡ °³¹ß µî ´Ù¾çÇÑ Á¦Ç° Çõ½ÅÀÌ ´Ù¸¥ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ »õ·Î¿î ±â°è ÃàÀº Åõ¼® ³» ÀúÇ÷¾ÐÀÇ ¿¹¹æ, Åõ¼® Áß ¸ð´ÏÅ͸µ °³¼±, ÀüÀÚ ÀÇ·á ±â·Ï(EMR) À¯Áö¿¡ µµ¿òÀÌ µË´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦Ç° Á¦Á¶¾÷ü °¢»ç´Â °¡Á¤¿¡¼­ÀÇ Äɾ »ç¿ëÇÒ ¼ö ÀÖ´Â ÈÞ´ë¿ëÀ¸·Î °æÁ¦ÀûÀÎ Ç÷¾×Á¤È­ÀåÄ¡ÀÇ °³¹ßµµ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ±âŸ¿¡µµ ´ëÁßÀÇ °Ç°­ ÀǽÄÀÌ ³ô¾ÆÁö°í, ƯÈ÷ ½ÅÈï °æÁ¦ ±¹°¡¿¡¼­ÀÇ ÀÇ·á ÀÎÇÁ¶ó °³¼± µîÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°èÀÇ Ç÷¾×Á¤È­ÀåÄ¡ ½ÃÀå ±Ô¸ð´Â?
  • ¿¹Ãø ±â°£ µ¿¾È ¼¼°èÀÇ Ç÷¾×Á¤È­ÀåÄ¡ ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • ¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀåÀÇ Á¦Ç° À¯Çüº° ³»¿ªÀº?
  • Ç÷¾× Á¤È­ Àåºñ ½ÃÀåÀÇ ÀûÀÀÁõº° ³»¿ªÀº?
  • ¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ³»¿ªÀº?
  • Ç÷¾× Á¤È­ Àåºñ ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀå¿¡¼­ ÁÖ¿ä ÁøÃâ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Ç÷¾× Á¤È­ Àåºñ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª: Á¦Ç° À¯Çüº°

  • ÈÞ´ë¿ë
  • °ÅÄ¡Çü

Á¦7Àå ½ÃÀå ºÐ¼® : ÀûÀÀÁõº°

  • ÆÐÇ÷Áõ
  • ½ÅÀå Áúȯ
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • Åõ¼® ¼¾ÅÍ
  • ±âŸ

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Aethlon Medical Inc.
    • Asahi Kasei Corporation
    • B. Braun Melsungen AG
    • Baxter International Inc.
    • Cerus Corporation
    • CytoSorbents Corporation
    • Fresenius SE & Co. KGaA
    • Healthwell Medical Tech. Co. Ltd.
    • Jafron Biomedical Co. Ltd.
    • Kaneka Corporation
    • Medtronic plc
    • Nikkiso Co ltd.
    • Spectral Medical Inc.
BJH 24.09.20

The global blood purification equipment market size reached US$ 20.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6% during 2024-2032.

Blood purification equipment refers to the medical devices used for extracting and purifying the patient's blood. The equipment withdraws the blood to remove impurities and pumps the purified blood back into the body. Some of the commonly used equipment include hemodialysis, blood filtration, continuous renal replacement therapy (CRRT), hemoperfusion and plasma exchange devices. They are commonly utilized for the treatment of organ or renal failures and immune-metabolic disorders and for plasmapheresis procedures and are widely used across hospitals, clinics and ambulatory surgical centers.

Blood Purification Equipment Market Trends:

The increasing prevalence of metabolic, immune and kidney-related disorders across the globe is one of the key factors driving the growth of the market. Furthermore, rising geriatric population, which is more susceptible to ailments, such as diabetes, hypertension and renal failure, is providing a thrust to the market growth. As the coronavirus disease (COVID-19) continues to spread, there is a significant increase in the requirement for blood purification devices across healthcare centers. These devices filter the pathogens, cytokines and other inflammatory mediators from the blood to improve the cell's immune response. Additionally, various product innovations, such as the development of equipment with biofeedback loops and personalized dialysis prescription capabilities, are acting as other growth-inducing factors. These novel variants aid in preventing intradialytic hypotension, improving monitoring during dialysis and maintaining electronic medical records (EMRs). In line with this, product manufacturers are also developing portable and economical blood purification equipment, which can be used for at-home care settings. Other factors, including rising health consciousness among the masses, along with improvements in the medical infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global blood purification equipment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, indication and end user.

Breakup by Product Type:

Portable

Stationary

Breakup by Indication:

Sepsis

Renal Diseases

Others

Breakup by End User:

Hospitals and Clinics

Dialysis Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Aethlon Medical Inc., Asahi Kasei Corporation, B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, CytoSorbents Corporation, Fresenius SE & Co. KGaA, Healthwell Medical Tech. Co. Ltd., Jafron Biomedical Co. Ltd., Kaneka Corporation, Medtronic plc, Nikkiso Co ltd., and Spectral Medical Inc.

Key Questions Answered in This Report

  • 1. What was the size of the global blood purification equipment market in 2023?
  • 2. What is the expected growth rate of the global blood purification equipment market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global blood purification equipment market?
  • 4. What are the key factors driving the global blood purification equipment market?
  • 5. What is the breakup of the global blood purification equipment market based on the product type?
  • 6. What is the breakup of the global blood purification equipment market based on the indication?
  • 7. What is the breakup of the global blood purification equipment market based on the end user?
  • 8. What are the key regions in the global blood purification equipment market?
  • 9. Who are the key players/companies in the global blood purification equipment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Blood Purification Equipment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Portable
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Stationary
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Sepsis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Renal Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Dialysis Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aethlon Medical Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Asahi Kasei Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 B. Braun Melsungen AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Baxter International Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Cerus Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 CytoSorbents Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Fresenius SE & Co. KGaA
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Healthwell Medical Tech. Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Jafron Biomedical Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Kaneka Corporation
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Medtronic plc
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Nikkiso Co ltd.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis
    • 14.3.13 Spectral Medical Inc.
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 Financials
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦